well that is exactly what Phylogica are doing & one of the key points of their business model as it spreads the risk unlike many other biotechnology companies that have their hand firmly fixed in one key area should it fail it becomes catastrophic.
PYC's platform & library of patented peptides is put forward to identify the leads, then it becomes the majors side of business to carry through the further stages, yet the company still benefits through the milestones / royalties along the road....
Look at the diversity of issues they are targeting on the initial 3 partners alone..
Roche - Intracelluar targets
AstraZeneca - Hospital acquired infections
Pfizer - Broad scope of novel peptide vaccines
what's next ?
PYC Price at posting:
7.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)